Quoin Pharmaceuticals, Ltd.

NasdaqCM:QNRX Stock Report

Market Cap: US$2.7m

Quoin Pharmaceuticals Management

Management criteria checks 2/4

Quoin Pharmaceuticals' CEO is Michael Myers, appointed in Mar 2018, has a tenure of 6.17 years. total yearly compensation is $954.06K, comprised of 63.1% salary and 36.9% bonuses, including company stock and options. directly owns 0.25% of the company’s shares, worth $6.83K. The average tenure of the management team and the board of directors is 6.2 years and 2.6 years respectively.

Key information

Michael Myers

Chief executive officer

US$954.1k

Total compensation

CEO salary percentage63.1%
CEO tenure6.2yrs
CEO ownership0.3%
Management average tenure6.2yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Quoin stock soars 22% on plans to start 2nd trial of QRX003 for rare skin disorder

Oct 18

Quoin Pharmaceuticals GAAP EPS of -$3.24

Aug 18

Quoin Pharmaceuticals plunges on pricing $16.8M upsized stock offering

Aug 05

CEO Compensation Analysis

How has Michael Myers's remuneration changed compared to Quoin Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$954kUS$602k

-US$9m

Sep 30 2023n/an/a

-US$9m

Jun 30 2023n/an/a

-US$10m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$2mUS$550k

-US$9m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$19m

Dec 31 2021US$1mUS$519k

-US$21m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$10m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$579kUS$500k

-US$2m

Compensation vs Market: Michael's total compensation ($USD954.06K) is above average for companies of similar size in the US market ($USD674.55K).

Compensation vs Earnings: Michael's compensation has been consistent with company performance over the past year.


CEO

Michael Myers (61 yo)

6.2yrs

Tenure

US$954,063

Compensation

Dr. Michael Myers, Ph D., has been an Independent Director at Squarex Pharmaceutical Corp., since November 2022. He serves as Chief Executive Officer and Chairman of Quoin Pharmaceuticals, Ltd.from Octobe...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Myers
Co-Founder6.2yrsUS$954.06k0.25%
$ 6.8k
Denise Carter
Co-Founder6.2yrsUS$830.07k0.25%
$ 6.8k
Gordon Dunn
Chief Financial Officer2.5yrsUS$1.45m0%
$ 0

6.2yrs

Average Tenure

59yo

Average Age

Experienced Management: QNRX's management team is seasoned and experienced (6.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Myers
Co-Founder2.6yrsUS$954.06k0.25%
$ 6.8k
Denise Carter
Co-Founder2.6yrsUS$830.07k0.25%
$ 6.8k
Michael Sember
Independent Director2.6yrsUS$107.62k0%
$ 0
Joseph Cooper
Independent Director2.6yrsUS$112.62k0%
$ 0
Dennis Langer
Independent Director2.6yrsUS$117.62k0.0095%
$ 255.6
James Culverwell
Independent Director2.6yrsUS$122.62k0.0086%
$ 231.4
Natalie Leong
Independent Director2.6yrsUS$122.62k0%
$ 0
Alan Irvine
Scientific Advisorno datano datano data
Amy Paller
Scientific Advisorno datano datano data

2.6yrs

Average Tenure

65yo

Average Age

Experienced Board: QNRX's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.